Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer

Zuo, Fei; Yin, Lei; Xi, Yang; Wu, Wei; Zhong, Jing; Da, Miao; Han, Shuwen

doi:10.1186/s13099-019-0299-4

Cited by 22 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies looked at changes in the microbiome in patients receiving chemotherapy [11]. These studies showed that chemotherapy alters the microbiome and suggested an association between the microbiome and acute chemotherapy toxicities, mainly in the gastrointestinal system [12][13][14]. None of these studies looked at weight and late metabolic effects of chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies

Uzan-Yulzari

Morr

Tareef-Nabwani

et al. 2020

BMC Med

View full text Add to dashboard Cite

Background Adjuvant chemotherapy induces weight gain, glucose intolerance, and hypertension in about a third of women. The mechanisms underlying these events have not been defined. This study assessed the association between the microbiome and weight gain in patients treated with adjuvant chemotherapy for breast and gynecological cancers. Methods Patients were recruited before starting adjuvant therapy. Weight and height were measured before treatment and 4–6 weeks after treatment completion. Weight gain was defined as an increase of 3% or more in body weight. A stool sample was collected before treatment, and 16S rRNA gene sequencing was performed. Data regarding oncological therapy, menopausal status, and antibiotic use was prospectively collected. Patients were excluded if they were treated by antibiotics during the study. Fecal transplant experiments from patients were conducted using Swiss Webster germ-free mice. Results Thirty-three patients were recruited; of them, 9 gained 3.5–10.6% of baseline weight. The pretreatment microbiome of women who gained weight following treatment was significantly different in diversity and taxonomy from that of control women. Fecal microbiota transplantation from pretreatment samples of patients that gained weight induced metabolic changes in germ-free mice compared to mice transplanted with pretreatment fecal samples from the control women. Conclusion The microbiome composition is predictive of weight gain following adjuvant chemotherapy and induces adverse metabolic changes in germ-free mice, suggesting it contributes to adverse metabolic changes seen in patients. Confirmation of these results in a larger patient cohort is warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies

Uzan-Yulzari

Morr

Tareef-Nabwani

et al. 2020

BMC Med

View full text Add to dashboard Cite

show abstract

“…The seventeen selected studies included a total of 742 patients with a range of 8 – 126 participants in each of the studies. Cancers studied included CRC (n=5) ( 26 , 29 , 38 , 39 ), AML (n=3) ( 28 , 30 , 31 ), BCa (n=2) ( 24 , 36 ), Non-Hodgkin’s lymphoma (n=2) ( 32 , 33 ), lung cancer (n=1) ( 23 ), ovarian cancer (n=1) ( 27 ), liver cancer (n=1) ( 25 ), and various other types of cancers (n=3) ( 24 , 34 , 35 ). Six studies were conducted in China ( 23 , 26 , 27 , 29 , 38 , 39 ), three in the USA ( 28 , 30 , 31 ), two in France ( 32 , 33 ), two in Japan ( 25 , 36 ), and one each in Austria ( 35 ), Australia ( 34 ) and Israel ( 24 ).…”

Section: Resultsmentioning

confidence: 99%

Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review

Boyle

Pavlakis

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Increasing evidence suggests that the gut microbiome is associated with both cancer chemotherapy (CTX) outcomes and adverse events (AEs). This review examines the relationship between the gut microbiome and CTX as well as the impact of CTX on the gut microbiome. A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “chemotherapy” and “microbiome/microbiota”. The relevant literature was selected for use in this article. Seventeen studies were selected on participants with colorectal cancer (CRC; n=5), Acute Myeloid Leukemia (AML; n=3), Non-Hodgkin’s lymphoma (n=2), breast cancer (BCa; n=1), lung cancer (n=1), ovarian cancer (n=1), liver cancer (n=1), and various other types of cancers (n=3). Seven studies assessed the relationship between the gut microbiome and CTX with faecal samples collected prior to (n=3) and following CTX (n=4) showing that the gut microbiome is associated with both CTX efficacy and toxicity. Ten other prospective studies assessed the impact of CTX during treatment and found that CTX modulates the gut microbiome of people with cancer and that dysbiosis induced by the CTX is related to AEs. CTX adversely impacts the gut microbiome, inducing dysbiosis and is associated with CTX outcomes and AEs. Current evidence provides insights into the gut microbiome for clinicians, cancer survivors and the general public. More research is required to better understand and modify the impact of CTX on the gut microbiome.

show abstract

“…Various studies have reported statistically significant alterations in microbial composition following oxaliplatin administration. A study of 40 male BALB/c mice demonstrated increased abundance of Gram-negative bacteria in the gut following oxaliplatin administration, specifically a reduction in Parabacteroides and Prevotella 1 species and an increase in Prevotella 2 and Odoribacter in tissue samples [ 84 ]. These genera are from the Bacteroides phylum, which stems from the Bacteroidetes family—commensals to the GI tract but also opportunistic pathogens when the intestinal barrier is disrupted.…”

Section: Effects Of Antineoplastic Treatment On the Microbiomementioning

confidence: 99%

A Perspective on the Role of Microbiome for Colorectal Cancer Treatment

Kalasabail

Engelman

Zhang

et al. 2021

Cancers

View full text Add to dashboard Cite

In healthy hosts, trillions of microbes colonise the gut and oral cavity in a well-balanced state, maintaining a mutually beneficial relationship. Loss of this balance, termed dysbiosis, is strongly implicated in the pathogenesis of colorectal cancer (CRC). However, the roles of microbiota and dysbiosis in CRC treatment remain poorly understood. Recent studies suggest that the gut microbiota has the ability to affect the host response to chemotherapeutic agents by enhancing drug efficacy, promoting chemoresistance and mediating chemotherapy-induced toxicity and side effects via a variety of mechanisms. Several other studies have also proposed manipulation of the microbiota to optimise CRC treatment. In this review, we summarise the current advancement of knowledge on how microbiota and CRC treatments interact with each other and how this interaction may shed some light on the development of personalised microbiota manipulations that improve CRC treatment outcomes.

show abstract

Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer

Cited by 22 publications

References 42 publications

The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies

The intestinal microbiome, weight, and metabolic changes in women treated by adjuvant chemotherapy for breast and gynecological malignancies

Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review

A Perspective on the Role of Microbiome for Colorectal Cancer Treatment

Contact Info

Product

Resources

About